UBS Initiates Coverage On Amedisys with Sell Rating, Announces Price Target of $150
UBS initiates coverage on Amedisys (NASDAQ:AMED) with a Sell rating and announces Price Target of $150.
Related Posts
Revance Therapeutics Q2 EPS $(1.07) Misses $(1.05) Estimate, Sales $18.80M Beat $15.48M Estimate
Revance Therapeutics (NASDAQ:RVNC) reported quarterly losses of $(1.07) per share which missed the analyst consensus estimate of $(1.05) by 1.9 percent. This is a 4.46 percent increase over losses of $(1.12) per share
Barclays Initiates Coverage On NuVasive with Overweight Rating, Announces Price Target of $53
Barclays analyst Matt Miksic initiates coverage on NuVasive (NASDAQ:NUVA) with a Overweight rating and announces Price Target of $53.
Morgan Stanley Maintains Equal-Weight on Ameren, Lowers Price Target to $87
Morgan Stanley analyst Stephen Byrd maintains Ameren (NYSE:AEE) with a Equal-Weight and lowers the price target from $90 to $87.